(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer
NCT ID: NCT00673205
Last Updated: 2010-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
3588 participants
INTERVENTIONAL
1995-09-30
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Placebo
B
Bicalutamide
150mg p.o. daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bicalutamide
150mg p.o. daily
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient to be 18 years and above
Exclusion Criteria
* Previous history of another form of cancer (not prostate) within 5 years of study start.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manfred P Wirth, Professor
Role: PRINCIPAL_INVESTIGATOR
Technical University of Dresden, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Wooloongabba, Queensland, Australia
Research Site
East Melbourne, Victoria, Australia
Research Site
Graz, , Austria
Research Site
Linz, , Austria
Research Site
Mistelbach, , Austria
Research Site
Oberwart, , Austria
Research Site
Sankt Pölten, , Austria
Research Site
Antwerp, , Belgium
Research Site
Bruges, , Belgium
Research Site
Brussels, , Belgium
Research Site
Ghent, , Belgium
Research Site
Kortrijk, , Belgium
Research Site
Leuven, , Belgium
Research Site
Mons, , Belgium
Research Site
Ostend, , Belgium
Research Site
Seraing, , Belgium
Research Site
Brno, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Prague, , Czechia
Research Site
Berlin, , Germany
Research Site
Bonn, , Germany
Research Site
Dresden, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Heidelberg, , Germany
Research Site
Jena, , Germany
Research Site
Lübeck, , Germany
Research Site
Lüdenscheid, , Germany
Research Site
Mannheim, , Germany
Research Site
München, , Germany
Research Site
Regensburg, , Germany
Research Site
Sigmaringen, , Germany
Research Site
Budapest, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Dublin, , Ireland
Research Site
Haifa, , Israel
Research Site
Petah Tikva, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Tel Litwinsky, , Israel
Research Site
Bari, BA, Italy
Research Site
Bergamo, BG, Italy
Research Site
Belluno, BL, Italy
Research Site
Bologna, BO, Italy
Research Site
Brescia, BS, Italy
Research Site
Como, CO, Italy
Research Site
Cesena, FO, Italy
Research Site
Anagni, FR, Italy
Research Site
Carpi, MO, Italy
Research Site
Fidenza, PR, Italy
Research Site
Roma, Roma, Italy
Research Site
Siena, SI, Italy
Research Site
Torino, TO, Italy
Research Site
Treviso, TV, Italy
Research Site
Udine, UD, Italy
Research Site
Varese, VA, Italy
Research Site
Dolo, VE, Italy
Research Site
Portogruaro, VE, Italy
Research Site
México, , Mexico
Research Site
Amsterdam, , Netherlands
Research Site
Breda, , Netherlands
Research Site
Capelle aan den IJssel, , Netherlands
Research Site
Eindhoven, , Netherlands
Research Site
Enschede, , Netherlands
Research Site
Gouda, , Netherlands
Research Site
Heerlen, , Netherlands
Research Site
Maastricht, , Netherlands
Research Site
Nijmegen, , Netherlands
Research Site
Roosendaal, , Netherlands
Research Site
Rotterdam, , Netherlands
Research Site
Spijkenisse, , Netherlands
Research Site
Utrecht, , Netherlands
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Almada, , Portugal
Research Site
Coimbra, , Portugal
Research Site
Lisbon, , Portugal
Research Site
Porto, , Portugal
Research Site
Vila Nova de Gaia, , Portugal
Research Site
Somerset West, Cape Town, South Africa
Research Site
Bloemfontein, South Africa, South Africa
Research Site
Cape Town, , South Africa
Research Site
Durban, , South Africa
Research Site
George, , South Africa
Research Site
Johannesburg, , South Africa
Research Site
Pietermarizberg, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Granada, Andalusia, Spain
Research Site
Málaga, Andalusia, Spain
Research Site
Seville, Andalusia, Spain
Research Site
Bilbao, Basque Country, Spain
Research Site
Salamanca, Castille and León, Spain
Research Site
Guadalajara, Castille-La Mancha, Spain
Research Site
Badalona(barcelona), Catalonia, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Hospitalet de Llobregat(barcel, Catalonia, Spain
Research Site
A Coruña, Galicia, Spain
Research Site
Vigo(pontevedra), Galicia, Spain
Research Site
Alcalá de Henares, Madrid, Spain
Research Site
Getafe, Madrid, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Pamplona, Navarre, Spain
Research Site
Oviedo, Principality of Asturias, Spain
Research Site
San Juan(alicante), Valencia, Spain
Research Site
Valencia, Valencia, Spain
Research Site
Reading, Berkshire, United Kingdom
Research Site
Colchester, Essex, United Kingdom
Research Site
Barnet, Hertfordshire, United Kingdom
Research Site
Tooting, London, United Kingdom
Research Site
Belfast, Northern Ireland, United Kingdom
Research Site
Taunton, Somerset, United Kingdom
Research Site
Gwent, South Wales, United Kingdom
Research Site
Eastbourne, Sussex, United Kingdom
Research Site
Birmingham, West Midlands, United Kingdom
Research Site
Bolton, , United Kingdom
Research Site
Bristol, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Cleveland, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Falkirk, , United Kingdom
Research Site
Hull, , United Kingdom
Research Site
Kent, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Sheffield, , United Kingdom
Research Site
Shrewsbury, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 2010 Apr;105(8):1074-81. doi: 10.1111/j.1464-410X.2010.09319.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7054IL/0024
Identifier Type: -
Identifier Source: secondary_id
D6876C00024
Identifier Type: -
Identifier Source: org_study_id